Aptorum Group LTD

Niki BioSolutions, Inc. (NIKI) has filed an 8-K detailing its corporate PowerPoint presentation, outlining the completion of its merger with Aptorum Group and its subsidiary DiamiR Biosciences, and presenting its strategic vision focused on Alzheimer's disease diagnostics and therapeutics.

Niki BioSolutions, Inc. has officially appointed Ian Huen as CEO and Alidad Mireskandari as President and COO, detailing their compensation and equity awards following a merger.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed an amendment to its Form 8-K to include the audited financial statements of DiamiR Biosciences Corp. following their merger.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) has filed its Form 8-K, providing interim financial statements post-merger with DiamiR Biosciences Corp. and highlighting ongoing financial challenges.

Niki BioSolutions, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing at $1.00 or greater for ten consecutive business days.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) and DiamiR Biosciences Corp. have completed their merger, establishing a new entity focused on biopharmaceutical and diagnostics.

Kira S. Sheinerman has filed a Schedule 13D, reporting beneficial ownership of 1,515,293 shares, or 51.56%, of Niki BioSolutions, Inc. common stock, acquired as merger consideration.

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G indicating a complete divestment of its Class A Ordinary Shares in Aptorum Group Ltd, reducing its beneficial ownership to 0%.

A group of Scoggin entities and individuals filed a Schedule 13G for Aptorum Group Limited, confirming they hold no beneficial ownership in the company's Class A Ordinary Shares.

L1 Capital Global Opportunities Master Fund, Ltd. has reported a 7.2% beneficial ownership stake in Aptorum Group Ltd's Class A Ordinary Shares.